Literature DB >> 6609269

Anaphylatoxin formation during hemodialysis: effects of different dialyzer membranes.

D E Chenoweth, A K Cheung, L W Henderson.   

Abstract

Measurable complement activation resulting in the formation of both C3a and C5a anaphylatoxins was observed in 12 patients undergoing maintenance dialysis treatment with cuprophan hollow fiber dialyzers. Specific radioimmunoassay measurements demonstrated that these patients displayed significantly elevated levels of C3a antigen in the venous (outflow) line of the dialyzer after only 2 min of dialysis. During hemodialysis, venous plasma C3a levels continued to increase and became maximally elevated after 15 min. Thereafter, C3a concentrations gradually declined, suggesting that the rate of complement activation abates with continued cuprophan hemodialysis. Complement activation, as judged by venous plasma C3a levels, was also temporally correlated with hemodialysis leukopenia. The factor believed to be responsible for pulmonary vascular leukosequestration, C5a, could also be detected in venous plasma, but levels of this antigen were not strikingly elevated until the later stages of dialysis. By contrast, six patients dialyzed with polyacrylonitrile dialyzers failed to exhibit hemodialysis leukopenia and displayed only very modest increases in their plasma C3a levels during the initial phases of hemodialysis. These observations provide direct evidence that anaphylatoxin formation during hemodialysis is a transient phenomenon and indicate that the biocompatibility of dialysis membranes, as reflected by their complement activating potential, may be significantly different.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6609269     DOI: 10.1038/ki.1983.225

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  21 in total

Review 1.  beta 2-Microglobulin amyloidosis. A systemic amyloid disease affecting primarily synovium and bone in long-term dialysis patients.

Authors:  C P Maury
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

2.  Effects of two types of cobra venom factor on porcine complement activation and pulmonary artery pressure.

Authors:  A K Cheung; C J Parker; L Wilcox
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

3.  Development of a simple radioimmunoassay for human C3a.

Authors:  H R Lamche; E Paul; G Schlag; H Redl; D E Hammerschmidt
Journal:  Inflammation       Date:  1988-06       Impact factor: 4.092

Review 4.  Biological properties of human C5a: selected in vitro and in vivo studies.

Authors:  K B Yancey
Journal:  Clin Exp Immunol       Date:  1988-02       Impact factor: 4.330

5.  Plasma Complement Protein C3a Level Was Associated with Abdominal Aortic Calcification in Patients on Hemodialysis.

Authors:  Yaqin Wang; Yuanyi Miao; Kunjing Gong; Xuyang Cheng; Yuqing Chen; Ming-Hui Zhao
Journal:  J Cardiovasc Transl Res       Date:  2019-04-15       Impact factor: 4.132

6.  Complement activation in patients with renal failure as detected through the quantitation of fragments of the complement proteins C3, C5, and factor B.

Authors:  M Oppermann; M Haubitz; E Quentin; O Götze
Journal:  Klin Wochenschr       Date:  1988-09-15

Review 7.  Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis.

Authors:  Robert A DeAngelis; Edimara S Reis; Daniel Ricklin; John D Lambris
Journal:  Immunobiology       Date:  2012-11       Impact factor: 3.144

8.  Human complement protein D catabolism by the rat kidney.

Authors:  P W Sanders; J E Volanakis; S G Rostand; J H Galla
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

Review 9.  The role of the complement system in acute kidney injury.

Authors:  James W McCullough; Brandon Renner; Joshua M Thurman
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299

10.  Alteration of HDL Protein Composition with Hemodialysis Initiation.

Authors:  Ke Wang; Leila R Zelnick; Andrew N Hoofnagle; Tomas Vaisar; Clark M Henderson; Peter B Imrey; Cassianne Robinson-Cohen; Ian H de Boer; Yan-Ting Shiu; Jonathan Himmelfarb; Gerald J Beck; Bryan Kestenbaum
Journal:  Clin J Am Soc Nephrol       Date:  2018-07-25       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.